Opdivo-Yervoy Combo Showing Efficacy in Aggressive Prostate Cancer Patients with Select Mutations

Opdivo-Yervoy Combo Showing Efficacy in Aggressive Prostate Cancer Patients with Select Mutations
A combination of two approved immunotherapies — Opdivo (nivolumab) and Yervoy (ipilimumab) — appears to delay cancer progression and lengthen survival in a subset of patients with an aggressive form of castration-resistant prostate cancer, results from an ongoing pilot trial led by Johns Hopkins School of Medicine show. The study, “Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *